STOCK TITAN

Neumora has $85.7M cash, needs substantial funding

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Neumora Therapeutics, Inc. (NMRA) reported third-quarter 2026 results and pipeline updates, including submission of an Investigational New Drug application for NMRA-215 to the U.S. Food and Drug Administration. Net loss was $34.4 million, compared with $56.8 million in the third quarter of 2025. Research and development expense was $22.6 million versus $40.5 million, and general and administrative expense was $10.8 million versus $12.2 million. Cash and cash equivalents were $85.7 million as of September 30, 2026, compared with $182.5 million as of December 31, 2025. Neumora said substantial additional funding will be required to continue operations and complete development and, if approved, commercialization of its candidates; it said there is no assurance funding will be available or on what terms, and provided no updated financial runway guidance.

Preclinical diet-induced-obesity mouse studies of NMRA-215 reported weight loss of up to 19% as monotherapy and up to 26% with semaglutide. In a multiple ascending dose expansion cohort, 30 mg twice daily of NMRA-511 in healthy elderly participants had a favorable safety and tolerability profile, no serious adverse events, and dose-proportional increases in exposure compared with 20 mg twice daily evaluated in a Phase 1b study. Neumora said NMRA-511 is Phase 2 enabled. A Phase 1 multiple ascending dose study of NMRA-898 is ongoing in healthy volunteers and patients with stable schizophrenia.

1 point · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 1 point

Hollow bars mark forward-looking points. How the balance works

Positive

  • Moderate pointThird-quarter net loss fell to $34.4 million from $56.8 million.

Negative

  • Moderate point. Forward-looking: it has not happened yet and may not happen.September 30 cash was $85.7 million; Neumora says substantial additional funding is required.
Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Net loss $34.4 million Third quarter of 2026; compared with $56.8 million in the third quarter of 2025
Research and development expense $22.6 million Third quarter of 2026; compared with $40.5 million in the third quarter of 2025
General and administrative expense $10.8 million Third quarter of 2026; compared with $12.2 million in the third quarter of 2025
Cash and cash equivalents $85.7 million As of September 30, 2026; compared with $182.5 million as of December 31, 2025
Net loss per share, basic and diluted ($0.18) per share Third quarter of 2026; compared with ($0.35) per share in the third quarter of 2025
NMRA-215 monotherapy weight loss Up to 19% Preclinical diet-induced-obesity mouse studies
NMRA-215 weight loss with semaglutide Up to 26% Preclinical diet-induced-obesity mouse studies
NMRA-511 dose 30 mg twice daily Multiple ascending dose expansion cohort in healthy elderly participants; compared with 20 mg twice daily evaluated in the Phase 1b study
Investigational New Drug (IND) application regulatory
"submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration"
An investigational new drug (IND) application is a formal request submitted to a drug regulator asking permission to begin testing a new medicine in people. It compiles lab results, manufacturing details and proposed human trial plans so regulators can judge safety before human studies start; for investors, an accepted IND is a key milestone that opens the clinical development pathway and can materially change a company’s risk profile and potential value, like getting a license to road-test a prototype.
NLRP3 inhibitor medical
"NMRA-215, a potentially best-in-class, highly brain-penetrant oral NLRP3 inhibitor"
An NLRP3 inhibitor is a substance that blocks a specific part of the body’s immune system responsible for inflammation. By preventing excessive inflammation, it has potential uses in treating certain diseases, which may affect the value of related biotech or pharmaceutical companies. For investors, understanding NLRP3 inhibitors can offer insights into emerging medical therapies and future market opportunities.
multiple ascending dose (MAD) medical
"results from the multiple ascending dose (MAD) expansion cohort"
Multiple ascending dose (MAD) is a research process used to test how a new medicine affects the body when given in increasing amounts over several doses. It helps researchers find the safest and most effective dose before the drug is widely used. For investors, understanding MAD studies is important because successful results can signal progress toward new treatments and potential future profits.
dose-proportional increase in exposure technical
"Dose-proportional increase in exposure observed in multiple ascending dose (MAD) expansion cohort"
positive allosteric modulator medical
"NMRA-898 (M4 Positive Allosteric Modulator)"
A positive allosteric modulator is a drug-like molecule that attaches to a different spot on a biological target than the body’s own messenger, and increases the target’s response when that natural messenger is present—like turning up a volume knob rather than replacing the song. For investors, these agents can boost a therapy’s effectiveness or safety without directly activating the target, offering potential competitive advantage, clearer combination strategies, and distinct patent or regulatory value.
diet-induced obesity (DIO) medical
"preclinical findings from diet-induced obesity (DIO) mouse studies"
Net loss $34.4 million Compared with $56.8 million in the third quarter of 2025
Research and development expense $22.6 million Compared with $40.5 million in the third quarter of 2025
General and administrative expense $10.8 million Compared with $12.2 million in the third quarter of 2025
Net loss per share, basic and diluted ($0.18) per share Compared with ($0.35) per share in the third quarter of 2025
Cash and cash equivalents $85.7 million Compared with $182.5 million as of December 31, 2025
Guidance

Neumora is not providing updated financial runway guidance. It said substantial additional funding will be required to continue operations and complete development and, if approved, commercialization of its product candidates, and that there can be no assurance such funding will be available or on what terms.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What was NMRA's net loss in the third quarter of 2026?

Neumora reported a net loss of $34.4 million for the third quarter ended September 30, 2026, compared with $56.8 million for the same period in 2025.

What did NMRA report for its NMRA-215 obesity program?

Neumora submitted an Investigational New Drug application for NMRA-215 to the U.S. Food and Drug Administration. Preclinical diet-induced-obesity mouse studies reported weight loss of up to 19% as monotherapy and up to 26% with semaglutide.

What were the NMRA-511 multiple ascending dose results?

In healthy elderly participants, a 30 mg twice-daily dose showed a favorable safety and tolerability profile with no serious adverse events and dose-proportional increases in exposure compared with the 20 mg twice-daily dose evaluated in the Phase 1b study.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
0001885522false00018855222026-11-162026-11-16

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 16, 2026

 

 

Neumora Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-41802

84-4367680

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

260 Arsenal Place, Suite 1

 

Watertown, Massachusetts

 

02472

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 857 760-0900

 

 

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, $0.0001 par value per share

 

NMRA

 

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 


Item 2.02 Results of Operations and Financial Condition.

On November 16, 2026, Neumora Therapeutics, Inc. (“Neumora” or the “Company”) announced its financial results for the third quarter ended September 30, 2026. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information furnished pursuant to this Item 2.02 of this Current Report on Form 8-K, including the attached Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

Exhibit Number

 

Description

99.1

 

Press Release dated November 16, 2026

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

NEUMORA THERAPEUTICS, INC.

 

 

 

 

Date:

November 16, 2026

By:

/s/ Michael Milligan

 

 

 

Michael Milligan
Chief Financial Officer

 


Exhibit 99.1

 

img49001591_0.gif

 

Neumora Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

 

IND application for NMRA-215 (NLRP3 inhibitor) submitted to the U.S. Food and Drug Administration

 

Dose-proportional increase in exposure observed in multiple ascending dose (MAD) expansion cohort with NMRA-511 (V1aR antagonist), suggesting potential to build on the efficacy profile demonstrated in Phase 1b study

 

WATERTOWN, Mass., November 16, 2026 – Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced financial results for the third quarter ended September 30, 2026, and provided a business update.

 

“We’ve been in a period of strong execution across our pipeline, including the submission of our IND for NMRA-215 in obesity and the NMRA-511 data we reported today, which suggest we can build on the unsurpassed efficacy seen in our Phase 1b study in AD agitation,” said Joshua Pinto, Ph.D., president and chief executive officer, Neumora. “We remain disciplined in allocating capital to the programs with the greatest potential to create value for patients and shareholders, and we are actively evaluating options to fund our lead programs through their next value inflection points.”

 

KEY PIPELINE HIGHLIGHTS

 

NMRA-215 (NLRP3 Inhibitor):

Neumora is developing NMRA-215, a potentially best-in-class, highly brain-penetrant oral NLRP3 inhibitor, for the treatment of obesity and cardiometabolic disease and has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration.

 

Additionally, Neumora today announced the presentation of preclinical results from NMRA-215 at ObesityWeek 2026. The presentation highlighted preclinical findings from diet-induced obesity (DIO) mouse studies of NMRA-215, in which NMRA-215 demonstrated class-leading weight loss of up to 19% as a monotherapy with incretin-like induction and up to 26% in combination with semaglutide.

 

NMRA-511 (Vasopressin 1a Receptor Antagonist):

Neumora today announced results from the multiple ascending dose (MAD) expansion cohort evaluating a 30 mg BID dose of NMRA-511 in healthy elderly participants. The 30 mg BID dose demonstrated a favorable safety and tolerability profile with no serious adverse events, and dose-proportional increases in exposure compared to the 20 mg BID dose evaluated in the Phase 1b study. The Company believes the 30 mg BID dose may build on the strong efficacy established with the 20 mg BID dose in the Phase 1b study, and the program is Phase 2 enabled.

 

Additionally, Neumora recently presented data from the NMRA-511 Phase 1b study at the Neuroscience Education Institute (NEI) Fall Congress.

 

NMRA-898 (M4 Positive Allosteric Modulator):

The Phase 1 MAD study with NMRA-898 in healthy volunteers and patients with stable schizophrenia is ongoing.

 

THIRD QUARTER 2026 FINANCIAL RESULTS

 

•
Cash Position: As of September 30, 2026, Neumora had cash and cash equivalents of $85.7 million.

 

•
Financial Guidance: Neumora is not providing updated financial runway guidance. As disclosed in our Quarterly Report on Form 10-Q being filed with the Securities and Exchange Commission today, to continue to operate our business and complete the development and, if approved, commercialization of our product candidates, we will require substantial additional funding and there can be no assurance such funding will be available to us at all or as to the terms on which we are able to obtain such financing.

 

 


 

•
R&D Expense: Research and development expenses for the third quarter of 2026 were $22.6 million, as compared to $40.5 million for the same period in 2025. The decrease was primarily due to a reduction in clinical trial costs, and lower personnel-related costs.

 

•
G&A Expense: General and administrative expenses for the third quarter of 2026 were $10.8 million, as compared to $12.2 million for the same period in 2025. The decrease was primarily attributable to lower personnel-related costs.

 

•
Net Loss: The Company reported a net loss of $34.4 million for the third quarter of 2026, as compared to $56.8 million for the same period in 2025.

 

About Neumora

Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded to confront the greatest medical challenges of our generation by taking a fundamentally different approach to the way treatments for brain diseases are developed. Our therapeutic pipeline currently consists of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases. Neumora’s mission is to redefine neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients.

 

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements about Neumora Therapeutics, Inc. (the “Company,” “we,” “us,” or “our”) within the meaning of the federal securities laws, including statements related to: Neumora’s intention to redefine neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients; the timing, progress and plans for its therapeutic development programs, including the timing of clinical trial initiation and data readouts, including for the NMRA-215, NMRA-511 and NMRA-898 studies; support for continued development, and upcoming milestones and catalysts; expectations and projections regarding future operating results and financial performance, including our ability to continue to operate our business and complete the development and commercialization of our product candidates, if approved; our ability to obtain additional funding; and other statements identified by words such as “could,” “expects,” “intends,” “may,” “plans,” “potential,” “should,” “will,” “would,” or similar expressions and the negatives of those terms. Other than statements of historical facts, all statements contained in this press release are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are subject to risks and uncertainties that could cause the actual results to be materially different from the information expressed or implied by these forward-looking statements, including, among others: the risks related to the inherent uncertainty of clinical drug development and unpredictability and lengthy process for obtaining regulatory approvals; risks related to the timely initiation and enrollment in our clinical trials; risks related to our reliance on third parties, including CROs; risks related to serious or undesirable side effects of our therapeutic candidates; risks related to our ability to utilize and protect our intellectual property rights; and other matters that could affect sufficiency of capital resources to fund operations. For a detailed discussion of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Neumora’s business in general, please refer to the risk factors identified in the Company’s filings with the Securities and Exchange Commission (SEC), including but not limited to its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 which was filed with the SEC on or about the date hereof. Forward-looking statements speak only as of the date hereof, and, except as required by law, Neumora undertakes no obligation to update or revise these forward-looking statements. Our results for the quarter ended September 30, 2026 are not necessarily indicative of our operating results for any future periods.

 

 


 

Financial Tables

 

NEUMORA THERAPEUTICS

Unaudited Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except per share amounts)

 

 

 

Three Months Ended
September 30,

 

 

Nine Months Ended
September 30,

 

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

$

22,614

 

 

$

40,520

 

 

$

90,495

 

 

$

131,395

 

General and administrative

 

 

10,795

 

 

 

12,180

 

 

 

37,968

 

 

 

46,281

 

Acquired in-process research and development

 

 

—

 

 

 

5,000

 

 

 

—

 

 

 

5,000

 

Total operating expenses

 

 

33,409

 

 

 

57,700

 

 

 

128,463

 

 

 

182,676

 

Loss from operations

 

 

(33,409

)

 

 

(57,700

)

 

 

(128,463

)

 

 

(182,676

)

Other income (expense):

 

 

 

 

 

 

 

 

 

 

 

 

Interest income

 

 

809

 

 

 

1,685

 

 

 

2,975

 

 

 

7,009

 

Interest expense

 

 

(1,831

)

 

 

(747

)

 

 

(5,505

)

 

 

(1,183

)

Other income (expense), net

 

 

(9

)

 

 

7

 

 

 

44

 

 

 

(498

)

Total other income (expense)

 

 

(1,031

)

 

 

945

 

 

 

(2,486

)

 

 

5,328

 

Net loss before income taxes

 

 

(34,440

)

 

 

(56,755

)

 

 

(130,949

)

 

 

(177,348

)

Provision for income taxes

 

 

—

 

 

 

—

 

 

 

31

 

 

 

130

 

Net loss

 

$

(34,440

)

 

$

(56,755

)

 

$

(130,980

)

 

$

(177,478

)

Other comprehensive loss:

 

 

 

 

 

 

 

 

 

 

 

 

Unrealized gain (loss) on marketable securities

 

 

—

 

 

 

24

 

 

 

—

 

 

 

(53

)

Comprehensive loss

 

$

(34,440

)

 

$

(56,731

)

 

$

(130,980

)

 

$

(177,531

)

Net loss per share, basic and diluted

 

$

(0.18

)

 

$

(0.35

)

 

$

(0.71

)

 

$

(1.10

)

Weighted-average shares outstanding, basic and diluted

 

 

187,896

 

 

 

161,838

 

 

 

184,322

 

 

 

161,663

 

 

 

Unaudited Condensed Consolidated Balance Sheets

(in thousands)

 

 

 

September 30,
2026

 

 

December 31,
2025

 

Cash and cash equivalents

 

$

85,654

 

 

$

182,530

 

Total assets

 

$

95,046

 

 

$

191,047

 

Total liabilities

 

$

76,495

 

 

$

87,176

 

Total stockholders’ equity

 

$

18,551

 

 

$

103,871

 

 

 

Neumora Contact

Helen Rubinstein

617-402-5700

Helen.Rubinstein@neumoratx.com

 

 


Filing Exhibits & Attachments

2 documents

Keep reading